Clinical Trial

Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, therapeutic exploratory Phase 2 clinical trial designed to evaluate the efficacy and safety of NV01-A02 in pediatric participants diagnosed with Autism Spectrum Disorder (ASD).
Trial Details
NCT Number NCT06951854
Lead Sponsor Neuroventi Inc.
Conditions Autism Spectrum Disorder (ASD
Enrollment 105 participants
Start Date 2025-04-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-30